Anavex Highlights Oral Blarcamesine's Patient-Centric Alzheimer's Care At Alzheimer Europe Conference Via Prof. Dr. Timo Grimmer's Phase IIb/III Study Presentation

Author: Benzinga Newsdesk | October 10, 2025 06:31am

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Prof. Dr. Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study gave an oral presentation titled, "Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine" at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'.

Posted In: AVXL